ISLAMABAD – In a major step toward eliminating malaria, Pakistan has successfully completed a five-year clinical trial testing a single-dose treatment for Plasmodium vivax, the most common form of malaria in the country.
The study, known as the EFFORT trial, tested three different treatment plans in high-risk areas including Karachi and Thatta. These included:
- The traditional 14-day low-dose primaquine regimen
- A shorter 7-day high-dose course
- And a single dose of tafenoquine
Results showed that the shorter regimens, particularly the single-dose tafenoquine, were just as effective in preventing relapse, while offering the benefit of better patient compliance.
A Game-Changer for Public Health
Health experts say the findings could revolutionize how malaria is treated in Pakistan, where many patients fail to complete the longer course of medication. The simplified one-dose treatment could significantly improve adherence and reduce the chances of recurring infection.
“This trial focused on how treatments work in real-world conditions,” said Professor Kamala Thriemer, lead researcher from the Menzies School of Health Research. “It brings us a step closer to more practical solutions.”
What’s Next?
Authorities are now reviewing the results to decide if the new treatment should be rolled out nationally. If approved, it could become a key part of Pakistan’s anti-malaria strategy in the coming years.
This story has been reported by PakTribune. All rights reserved.